Roberto Nitsch graduated in Medical Biotechnology from the University of Naples (Italy) in where he also obtained his PhD in Molecular Genetics in. With an initial research focus on genetic and epigenetic regulation, he later moved to IMBA (Vienna) where he studied mouse genetics and cancer biology. Soon after, he became interested in recessive genetics and once CRISPR/Cas9 was discovered, he shifted focus towards genome engineering. He joined AstraZeneca in 2014 as Senior Research Scientist in Discovery Sciences in the Precise Genome Editing team. He was responsible for in vivo applications of CRISPR to the generation of translatable mouse models for drug discovery with focus on oncology models.